Enumeral Biomedical Holdings Inc fka ENUMQ

[undtrdr]

Our collaboration w/Pieris Pharmaceuticals $PIRS gets a nice shot in the arm with half of their market cap being paid cash up front to them, in a collaboration of their own with Servier, a pharmaceutical company headquartered in France....annual sales EUR4 Billion and 5 products to date in late pre-clinical or early development in immuno-oncology.

Under the collaboration, Pieris and Servier will initially pursue five bispecific therapeutic programs, led by Pieris' PRS-332 program, a potentially best-in-class PD-1-targeting bispecific checkpoint inhibitor.

http://www.marketwired.com/press-release/pieris-pharmaceuticals-servier-forge-strategic-immuno-oncology-co-development-alliance-nasdaq-pirs-2186375.htm